• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Exclusives
    • Nutraceuticals
    • Markets
    • Health
    • Jobs
    • Events
    • Buyers' Guide
    • Showcases
    • More
  • Magazine
  • News
  • Exclusives
  • Nutraceuticals
  • Markets
  • Health
  • Jobs
  • Events
  • Buyers' Guide
  • Showcases
  • Current & Past Issues
    Features
    Columns
    Editorials
    Digital Edition
    Subscribe Now
    Advertise Now
    eNewsletter
    Editorial Guidelines
    Top Features
    Nutraceuticals for Men: Muscle Health and Performance Nutrition

    Aging in Place: Healthy Lifestyles Supplement Science-Based Solutions

    Getting an Edge in Esports: Meeting the Health Needs of Competitive Gamers

    Beyond CBD: Cannabis Compounds Warrant Recognition and More Research

    Leveling Out the Energy Segment for Mainstream, and Rethinking Caffeine
    Breaking News
    Certifications, Approvals and Patents
    Exclusives
    Industry & Market News
    People
    Products
    Regulatory
    Research
    Supplier News
    Supplier Insights
    Live From Shows
    Top News
    Bilberon Bilberry Extract Receives U.S. Patent For Eye Strain, Neck/Shoulder Pain

    Jordan Process Receives Nutrasource ICAP Certification for CBD

    FDA Warns About Steroids or Steroid-Like Substances in Bodybuilding Supplements

    Nootropics and Adaptogens Respond to Demand for Mind and Mood Support

    Sabinsa Honors 70th Anniversary of Diplomacy Between India and Japan
    Exclusives
    Blogs & Guest Articles
    Health E-Insights
    Area Code 420
    eBook
    Antioxidants
    Dairy-Based Ingredients
    Enzymes
    Fatty Acids
    Fiber & Carbohydrates
    Green Foods
    Herbs & Botanicals
    Marine Nutraceuticals
    Minerals
    Omega 3s
    Probiotics & Prebiotics
    Proteins, Peptides, Amino Acids
    Sweeteners
    Vitamins

    Bilberon Bilberry Extract Receives U.S. Patent For Eye Strain, Neck/Shoulder Pain

    Jordan Process Receives Nutrasource ICAP Certification for CBD

    Nootropics and Adaptogens Respond to Demand for Mind and Mood Support

    Sabinsa Honors 70th Anniversary of Diplomacy Between India and Japan

    Solvay Invests in Suanfarma’s Vanillin Production
    Consumer Trends
    Contract Manufacturing
    Cosmeceuticals / Nutricosmetics
    Delivery & Dosage Technologies
    Dietary Supplements
    Flavors & Colors
    Functional Foods & Beverages
    Healthcare Trends
    Medical Nutrition
    Mergers & Acquisitions
    Natural/Organic
    Nutrition Bars
    Packaging
    Pet Nutraceuticals
    Quality & Safety
    Regulations
    Research
    Testing
    World Markets

    Bilberon Bilberry Extract Receives U.S. Patent For Eye Strain, Neck/Shoulder Pain

    Jordan Process Receives Nutrasource ICAP Certification for CBD

    Senate Bill to Reauthorize FDA User Fees Includes Dietary Supplement Listing Provision

    FDA Warns About Steroids or Steroid-Like Substances in Bodybuilding Supplements

    Nootropics and Adaptogens Respond to Demand for Mind and Mood Support
    Bone & Joint Health
    Cancer Risk
    Cardiovascular Health
    Cognitive Function
    Diabetes & Blood Sugar Management
    Digestive Health
    Energy
    Eye Health
    Healthy Aging
    Immune Function
    Infant & Children's Health
    Inflammation
    Men's Health
    Mood Health & Sleep
    Oral Health
    Sexual & Reproductive Health
    Skin Health
    Sports Nutrition
    Weight Management/Weight Loss
    Women's Health

    Bilberon Bilberry Extract Receives U.S. Patent For Eye Strain, Neck/Shoulder Pain

    FDA Warns About Steroids or Steroid-Like Substances in Bodybuilding Supplements

    Nootropics and Adaptogens Respond to Demand for Mind and Mood Support

    Experts Debate Role of Supplements in Improving Public Health in EU

    GNC Adds Products from The Honest Company, Hers, and Womaness
    Industry Events
    Live From Show Events
    Webinars
    All Companies
    Categories
    Trade Associations
    Company Capabilities
    International Buyers Guide Companies
    Aiya America, Inc. (Aiya Matcha)

    ESHA Research

    Ecuadorian Rainforest

    Botanic Healthcare LLC

    Nutrition21, LLC
    Companies
    Product Releases
    News Releases
    Literature / Brochures
    White Papers
    Jobs
    VIdeos
    Services
    Add New Company
    International Buyers Guide Companies
    Aiya America, Inc. (Aiya Matcha)

    ESHA Research

    Ecuadorian Rainforest

    Botanic Healthcare LLC

    Nutrition21, LLC
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Digital Edition
      • eNewsletter Archive
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
    • Breaking News
    • Buyers' Guide
      • All Companies
      • Categories
      • Trade Associations
      • Company Capabilities
    • Nutraceuticals
      • Antioxidants
      • Dairy-Based Ingredients
      • Enzymes
      • Fatty Acids
      • Fiber & Carbohydrates
      • Green Foods
      • Herbs & Botanicals
      • Marine Nutraceuticals
      • Minerals
      • Omega 3s
      • Probiotics & Prebiotics
      • Proteins, Peptides, Amino Acids
      • Sweeteners
      • Vitamins
    • Markets
      • Consumer Trends
      • Contract Manufacturing
      • Cosmeceuticals / Nutricosmetics
      • Delivery & Dosage Technologies
      • Dietary Supplements
      • Flavors & Colors
      • Functional Foods & Beverages
      • Healthcare Trends
      • Medical Nutrition
      • Mergers & Acquisitions
      • Natural/Organic
      • Nutrition Bars
      • Packaging
      • Pet Nutraceuticals
      • Quality & Safety
      • Regulations
      • Research
      • Testing
      • World Markets
    • Health
      • Bone & Joint Health
      • Cancer Risk
      • Cardiovascular Health
      • Cognitive Function
      • Diabetes & Blood Sugar Management
      • Digestive Health
      • Energy
      • Eye Health
      • Healthy Aging
      • Immune Function
      • Infant & Children's Health
      • Inflammation
      • Men's Health
      • Mood Health & Sleep
      • Oral Health
      • Sexual & Reproductive Health
      • Skin Health
      • Sports Nutrition
      • Weight Management/Weight Loss
      • Women's Health
    • Online Exclusives
    • Webinars
    • Slideshows
    • Blogs & Guest Articles
    • Health E-Insights
    • Videos
    • Podcasts
    • Infographics
    • eBook
    • Whitepapers
    • Research
      • TrendSense
      • Monograph Center
      • White Papers
      • Research News
    • Jobs
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Supplier Showcases
      • Companies
      • Product Releases
      • News Releases
      • Literature / Brochures
      • White Papers
      • Jobs
      • VIdeos
      • Services
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    The Science of Cannabis & Cannabinoids

    Demand for Cannabis-based products is reaching fever-pitch.

    The Science of Cannabis & Cannabinoids
    Related CONTENT
    • Environmental, Social and Governance in the Cannabis Industry: A Perfect Storm is Brewing
    • Vitafoods Europe Event Info
    • How Blockchain Can Improve Transparency in the Dietary Supplement Industry
    • Beyond CBD: Cannabis Compounds Warrant Recognition and More Research
    • Cannabis Sales Predicted to Surpass $61 Billion Globally by 2026
    By Dilip Ghosh, PhD, FACN, nutriConnect09.10.18
    The cannabis plant, which may be different species (principally Cannabis sativa and Cannabis indica) or variants of the same species, is a dioecious entity and contains a number of unique resorcinol metabolites—estimates vary from 60-110. The most recognizable cannabinoid metabolite is delta-9-tetrahydrocannabinol (THC). Recent published data described the pharmacology of two other agents, cannabidiol (CBD) and delta-9-tetrahydrocannabivarin (THCV), and concluded that these compounds exhibited complex interactions with the human endocannabinoid system. Apart from these three compounds, other cannabinoids that have shown pharmacological effects include cannabigerol, cannabidivarin, cannabidiolic acid, and cannabichromene.

    Evidence of cannabis use for medical purposes can be traced back to 2737 BCE in ancient China. Since then there have been wide variations in the use and acceptance of cannabis as a drug therapy in Western medicine. In 1999, California was the only U.S. state that allowed patients to access cannabis for medicinal purposes. By 2016, there were 24 states where cannabis was available as a therapeutic agent, and three that had approved cannabis for recreational use.

    The Cannabis Plant
    Cannabis is one of the most complicated and challenging plants to taxonomists and arboriculturists. Cannabis is predominantly dioecious, with male and female flowers by definition developing on separate plants if grown naturally from seed. However, occasionally, it exhibits a monoecious (hermaphrodite) nature. Cannabis is normally a so-called “short-day plant.” At the end of summer, when the plants detect an increase in night length, they commence flowering. But after decades of research, scientists are now able to develop “auto flowering” cannabis plants, which aren’t as day-length sensitive, and start flowering when they are only about 2 weeks old. For the production of cannabinoids, all-female crops are preferred, because male plants produce much lower quantities of cannabinoids. The cannabinoids are predominantly, if not entirely, synthesized and sequestered in small structures called glandular trichomes and this tissue is the female flower.

    Terminology & Usage
    Raw herbal (botanical) cannabis is any part of any plant of the genus Cannabis. The genus Cannabis belongs to the Cannabaceae family. Some people believe cannabis is a single species, with C. indica, C. sativa, and C. ruderalis as three different subspecies, while others consider them three different species of Cannabis.

    Plants grown for fiber and seed are commonly referred to as hemp, whereas cannabis extract refers to any preparation that is removed from the plant, usually by organic solvents to produce oil.

    Cannabinoids are a class of chemical compounds that have the typical cannabinoid skeleton in common and affect the cannabinoid receptors. Other than naturally occurring cannabinoids, a few synthetic cannabinoids are manufactured today as approved drugs (cannabinoid-based medicines).

    Common Usage. The hemp plant has been used across the globe for centuries in the production of rope, sail, cloth, and paper. There is strong anecdotal evidence of medicinal use of hemp from ancient China, India, and Egypt for centuries.

    The term “cannabis abuse” is a relatively recent viewpoint. In the 1970s, cannabis extract was widely availabile in Europe and North America as a “recreational drug.” The leaves (variously referred to as marijuana or herbal cannabis, among many other names) or resin derived mostly from the buds (known as hashish, or many other names) are typically smoked. Smoking involves measures of volatilization and pyrolysis, and results in a relatively poor delivery of metabolites.

    Therapeutic/Medicinal Use. Currently, there are a few cannabinoid-based medicines available for marketing in different countries: Nabiximols (Sativex)—oromucosal spray formulated from extracts of the C. sativa plant that contains the cannabinoids THC and CBD; Nabilone (Cesamet or Canemes)—oral capsules containing a synthetic cannabinoid similar to THC; Dronabinol (Marinol or Syndros)—oral capsules or an oral solution containing synthetic delta-9-THC. The U.S. FDA also recently approved Epidiolex (cannabidiol), an oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy.

    Nutraceutical/Lifestyle/Cosmetic Use. More peripheral cannabis products such as cosmetics, food/dietary supplements, edibles, oils, and recreational-use products, as well as fiber and biofuel applications may offer more return on investment than medicinal drugs, given the shorter path to market.

    Functional beverages containing cannabis are noteworthy and offer a unique delivery mechanism. At Vitafoods Europe 2018, Donny Mistarz, CSO and co-founder of Plantine Holdings Limited, noted that his company “can produce a fully neutral and water-soluble product with increased bioavailability, giving the formulators full control over the taste experience of their final products.” Plantine is a large vertically integrated producer, manufacturer, and distributor of hemp products.

    Chemistry of Cannabis
    Cannabis contains many unique resorcinol metabolites, but the exact number is still debatable. The best estimate is around 60-110. The most recognizable cannabinoid is delta-9-tetrahydrocannabinol (THC). Many recent studies identified and described the pharmacology of three of these agents—cannabidiol (CBD), delta-9-tetrahydrocannabivarin (THCV), cannabigerol (CBG)—and concluded that these compounds exhibited complex interactions with the endocannabinoid system. 

    In fresh plant material, these cannabinoids all exist in the cannabinoid acid forms, such as delta-9–tetrahydrocannabinolic acid (THCA) and cannabidiolic acid (CBDA). As the plant material ages or is heated, the acid molecules lose a carboxyl moiety. Decarboxylation results in the conversion of the cannabinoid acids into their neutral forms (e.g., CBDA→CBD).

    The major cannabinoids have multiple targets within the central nervous system and can modulate activity of neurons, glia, and microglia. But it is still not entirely clear which mechanism(s) are critical for therapeutic actions. It has long been known that delta-9-THC has partial agonist activity at the endocannabinoid receptors CB1 and CB2, though it also binds to other targets which may modulate neuronal excitability and neuro-inflammation. The actions of delta-9-THCV and delta-9-THCA are less well understood. In contrast to delta-9-THC, CBD has low affinity for CB1 and CB2 receptors, but anticonvulsant properties are linked to regulation of voltage gated potassium and sodium channels, and GPR55.

    The use of cannabis and cannabinoids for medical conditions has become more popularized in recent years around the world. There is growing evidence that cannabis and cannabinoids are efficacious for several conditions, such as chronic pain, spasticity, nausea, and vomiting associated with chemotherapy. However, effect is variable, the quality of evidence is moderate to low, and there is no conclusive evidence for which either cannabis or cannabinoids have been recommended as first line therapeutic agents.

    The largest 2015 meta-analysis (Whiting et al. 2015) revealed moderate quality proofs in favor of nabiximols, nabilone, dronabinol, or THC/CBD in treating spasticity from multiple sclerosis. The same level of proof was shown for nabiximols or smoked THC in the treatment of chronic cancer pain and neuropathic pain.

    The reduced risk perception associated with marijuana (C. sativa, C. indica), as well as the sudden outburst of the cannabis industry around recreational and medical usage, has led to its increased popularity and use particularly among young people. It is the first time in the history of the U.S. that adolescents smoke marijuana more than tobacco, an increasing tendency since 2010. The relationship between cannabis use and neuropsychiatric vulnerability is clearly complex. Based on the theoretical assumption, there is a possibility of an epigenetic memory mark due to early exposure in one’s lifetime. It will be important to investigate how different cannabinoids or other components of the cannabis plant and even their interactions (e.g., THC and CBD) influence behavioral, physiological, and epigenetic effects in long-term users.

    Cultivation & Medical-Grade Products
    Generally, plant-based drugs represent unusual challenges in the pharmaceutical world with respect to large-scale cultivation, processing, quality, and consistency. Additionally, considerable complexity derives from regulatory concerns, depending on the countries of production and marketing. Quality and authenticity are major issues when working with cannabis or interpreting data obtained from human studies using the plant or its extracts. There is considerable variability in genetic background, growth conditions, harvesting times, preparation handling, and so on. Craig Weller, COO of Bod Australia highlighted the importance of standardization of cannabis extract. His company used a specific extract ECs315 from a cloned plant (chemotype) using a patented extraction process. 

    In recent years, the production of cannabidiol-based medicinal materials for research has come into greater focus because of its potential therapeutic opportunities in childhood epilepsy syndromes and other disorders. Many companies optimized methods for growing cannabis chemotypes indoors in a tightly controlled growing environment. All female cannabis crops with high-CBD have also been grown outdoors. When the plant ages, the amount of cannabinoid has been found to generally increase, reaching the highest level at the budding stage and achieving a plateau before the onset of senescence. Because the whole plant does not mature at the same time, mature upper buds are harvested first (visual confirmation) and other branches are given more time to achieve their maturity.

    CBD is the main cannabinoid found in hemp floral tissue. The concentration of CBD in the dry floral tissue would typically be 2% weight for weight (w/w) or less. Bod Australia uses Swiss company Linnea’s CM5 (5% CBD) in its MediCabilis oil in the Australian market. Cannabis grown for recreational use, however, is dominated by the presence of THC. The THC content of floral tissue in modern varieties typically exceeds 20% w/w. Because of an extensive breeding program at GW Pharmaceuticals, the materials used to produce CBD for Epidiolex contain a similar cannabinoid concentration to the most potent THC varieties, with floral material typically containing over 20% CBD.

    Regulatory & Legal Status
    In 1937, the U.S. criminalized the use of cannabis, and as a result its consumption decreased rapidly. In recent decades, there has been growing interest in the wide range of medical uses of cannabis and its constituents. Globally, however, laws and regulations are substantially different between countries. Laws differentiate between raw herbal cannabis, cannabis extracts, and cannabinoid-based medicines. Both the European Medicines Agency (EMA) and the U.S. FDA have not approved the use of herbal cannabis or its extracts. The FDA has approved several cannabinoid-based medicines, as have 23 European countries, Australia, and Canada. In Australia, cannabis possession and use are currently illegal. But in several states and territories (South Australia, ACT, and Northern Territory) a small amount for personal use has been decriminalized. That means it’s illegal, but not a criminal offense. Canada’s Senate recently voted to legalize recreational marijuana.

    However, only four countries have fully authorized the medical use of herbal cannabis: Canada, Germany, Israel, and the Netherlands, together with more than 50% of the states in the U.S. Most regulators allow physicians to decide what specific indications they will prescribe cannabis for, but some regulators dictate only specific indications.

    Market Potential
    The gradual legalization of cannabis has led to an amazing flurry of product activity. As Mr. Weller said, “the history of the prohibition of cannabis is shameful.”

    In the U.S., cannabis is still illegal at a Federal level, but has been legalized in many states. As a result, sales have grown an estimated 30% in 2016 to reach $6.7 billion. There have been estimates that U.S. cannabis sales will reach $20.2 billion by 2021 and could even eclipse $50 billion by 2026. Combined global consumption is estimated as high as $500 billion by 2029.
    Big companies outside their core business are getting involved. For example, Constellation Brands, the parent company behind Corona, Modelo, Svedka, and many other alcoholic drinks recently boosted its stake in the Canadian cannabis company Canopy Growth to 38% (reportedly at $3.8 billion) and is planning to experiment with cannabis-infused drinks.

    Gibraltar-based company, Plantine Holdings Limited had recently introduced a fully neutral and water-soluble hemp powder with increased bioavailability for functional beverage formulations. It’s possible that several blockbuster cannabis-based drugs could reach massive global sales in markets such as pain, nausea, appetite, and convulsion or muscle spasm reduction. For example, Australian cannabis company AusCann is researching a drug to treat chronic and neuropathic pain—a market that is estimated to be $5 billion a year in Australia alone.

    In June 2018, Canada took a key step toward legalizing recreational marijuana after senators voted in favor of new legislation permitting nationwide use of the drug. Uruguay, in 2014, became the first country to legalize the sale and distribution of cannabis. Many industrialized countries are also considering making cannabis legal for recreational purposes. In more than 11 European countries, including the Netherlands, Belgium, and Spain, cannabis is legal for medicinal use or has been decriminalized. Australia joined the list of countries where medicinal cannabis became legal in 2016.

    The Way Forward
    Cannabis is the most widely used illicit drug in the developed world and its use has long been associated with negative social and economic outcomes. An estimated 170 million people worldwide consume cannabis daily in different forms.

    The scientific and business communities are experiencing unique challenges in using cannabinoids as therapeutic agents, including low bioavailability and potentially erratic absorption in oral formulations, significant accumulation in adipose and other tissues, and interactions with other drugs metabolized by the cytochrome P450 system. Some of these problems may be overcome by advanced novel delivery systems (oromucosal, transdermal) or through synthesis of related compounds with optimized properties.

    Today marks an interesting crossroads for cannabis-related drugs from both scientific and political perspectives. There is strong consumer hype in translating the promise, particularly in terms of multiple sclerosis and epilepsy. But there’s still more work to be done to provide convincing evidence to support these claims. However, most will agree that the absence of evidence doesn’t necessarily indicate an absence of effectiveness. Investigators must take all these challenges and undertake additional trials so that clinicians can be informed about how to best use this versatile medicine in future practice.

    References
    • Chandra S et al. 2017. Cannabis cultivation: Methodological issues for obtaining medical-grade product. Epilepsy & Behavior 70: 302–312.
    • Gaston TE and Daniel Friedman D. 2017. Pharmacology of cannabinoids in the treatment of epilepsy. Epilepsy & Behavior 70: 313–318
    • Goldenberg M et al. 2017. The impact of cannabis and cannabinoids for medical conditions on health-related quality of life: A systematic review and meta-analysis. Drug and Alcohol Dependence 174: 80–90
    • Szutorisza H and Hurd YL. 2018. High times for cannabis: Epigenetic imprint and its legacy on brain and behaviour. Neuroscience and Biobehavioral Reviews 85: 93–101.
    • Whiting P et al. 2015.  Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 313 :2456-2473.

    About the author: Dilip Ghosh, PhD, FACN, is director of nutriConnect, based in Sydney, Australia. He is also professionally involved with NICM, Western Sydney University, Australia, and is an Honorary Ambassador with the Global Harmonization Initiative (GHI). Dr. Ghosh received his PhD in biomedical science from University of Calcutta, India. He has been involved in drug development (both synthetic and natural) and functional food research and development both in academic and industry domains. Dr. Ghosh has published more than 90 papers in peer-reviewed journals, and he has authored many books, including: “Biotechnology in Functional Foods and Nutraceuticals,” “Innovation in Healthy and Functional Foods,” “Clinical Perspective of Functional Foods and Nutraceuticals,” and “Pharmaceuticals to Nutraceuticals: A Shift in Disease Prevention” under CRC Press. He can be reached at dghosh@optusnet.com.au; www.nutriconnect.com.au.
    Related Searches
    • China
    • Delivery Systems
    • Organic
    • Research
    Related Knowledge Center
    • Herbs & Botanicals
    • World Markets
    • Regulations
    Suggested For You
    Environmental, Social and Governance in the Cannabis Industry: A Perfect Storm is Brewing Environmental, Social and Governance in the Cannabis Industry: A Perfect Storm is Brewing
    Vitafoods Europe Event Info Vitafoods Europe Event Info
    How Blockchain Can Improve Transparency in the Dietary Supplement Industry How Blockchain Can Improve Transparency in the Dietary Supplement Industry
    Beyond CBD: Cannabis Compounds Warrant Recognition and More Research Beyond CBD: Cannabis Compounds Warrant Recognition and More Research
    BESO Wellness Taps Tradition to Offer Modern Cannabis Formulations BESO Wellness Taps Tradition to Offer Modern Cannabis Formulations
    Hemp and CBD Updates: Industry Still in the Weeds Hemp and CBD Updates: Industry Still in the Weeds
    Brand Obsession Has Entered the CBD Category Brand Obsession Has Entered the CBD Category
    Cannabis Sales Predicted to Surpass $61 Billion Globally by 2026 Cannabis Sales Predicted to Surpass $61 Billion Globally by 2026
    CBD and CBN Sleep Products Hit the High Notes CBD and CBN Sleep Products Hit the High Notes
    Single-Center Study Evaluates Effects of Novel Retinol and Cannabidiol Combination Topical on Facial Skin Single-Center Study Evaluates Effects of Novel Retinol and Cannabidiol Combination Topical on Facial Skin
    CBD in Topical Formulations CBD in Topical Formulations
    Lead the Hemp and CBD Market with Science Lead the Hemp and CBD Market with Science
    Keeping Score: CBD in Sports Keeping Score: CBD in Sports
    Open Book Extracts Announces Completion of Study on Rare Cannabinoids for Pain Open Book Extracts Announces Completion of Study on Rare Cannabinoids for Pain
    Hello Again Brand Sets to Lift Women’s Health with Cannabis Product Line Hello Again Brand Sets to Lift Women’s Health with Cannabis Product Line

    Related Content

    • Dietary Supplements | Healthcare Trends | Herbs & Botanicals | Natural/Organic | Regulations | World Markets
      Environmental, Social and Governance in the Cannabis Industry: A Perfect Storm is Brewing

      Environmental, Social and Governance in the Cannabis Industry: A Perfect Storm is Brewing

      Marc Ross discusses how companies getting in front of ESG are well-positioned to win investors, talent, and customers.
      By Sheldon Baker, CEO Baker Dillon Group LLC 05.03.22

    • Contract Manufacturing | Dietary Supplements
      Vitafoods Europe Event Info

      Vitafoods Europe Event Info

      The global nutraceutical conference
      04.20.22

    • Dietary Supplements | Healthcare Trends | Quality & Safety | World Markets
      How Blockchain Can Improve Transparency in the Dietary Supplement Industry

      How Blockchain Can Improve Transparency in the Dietary Supplement Industry

      Technology that can track a sequence of transactions helps build trust among stakeholders along the supply chain, as well as between consumers and brands.
      By Robert Galaza, CEO, TruTrace Technologies 04.14.22


    • Herbs & Botanicals | Research
      Beyond CBD: Cannabis Compounds Warrant Recognition and More Research

      Beyond CBD: Cannabis Compounds Warrant Recognition and More Research

      With growing consumer usage, scientists must continue exploring the many constituents of cannabis, their interactions, and potential health effects.
      By Sean Moloughney, Editor 04.14.22

    • Dietary Supplements | Healthcare Trends | Herbs & Botanicals
      Cannabis Sales Predicted to Surpass $61 Billion Globally by 2026

      Cannabis Sales Predicted to Surpass $61 Billion Globally by 2026

      While sales softened for most legal cannabis markets in the second half of 2021, new markets are driving growth, according to BDSA report.
      04.07.22

      Breaking News
      • Bilberon Bilberry Extract Receives U.S. Patent For Eye Strain, Neck/Shoulder Pain
      • Jordan Process Receives Nutrasource ICAP Certification for CBD
      • FDA Warns About Steroids or Steroid-Like Substances in Bodybuilding Supplements
      • Nootropics and Adaptogens Respond to Demand for Mind and Mood Support
      • Sabinsa Honors 70th Anniversary of Diplomacy Between India and Japan
      View Breaking News >
      CURRENT ISSUE

      May 2022

      • Aging in Place: Lifestyle Supplements Science-Based Solutions
      • Getting an Edge in Esports: Meeting Health & Nutrition Needs
      • Nutraceuticals for Men: Muscle Health and Performance Nutrition

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Bilberon Bilberry Extract Receives U.S. Patent For Eye Strain, Neck/Shoulder Pain
      Jordan Process Receives Nutrasource ICAP Certification for CBD
      FDA Warns About Steroids or Steroid-Like Substances in Bodybuilding Supplements
      Coatings World

      Latest Breaking News From Coatings World

      AGM Secures Exclusive Distribution Agreement with Indian Partner Imkemex
      Microban Announced as Lead Sponsor of BCF Annual Conference and Dinner 2022
      DIC’s Indian Subsidiary Begins Construction of Coating Resins Production Facility
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      Robocath Presents Results from R-Evolution Clinical Study
      Medtronic's Resolute Onyx Drug-Eluting Stent Shows Success for Left Main PCI
      Medtronic Shares 3-Year Renal Denervation Blood Pressure Trial Data
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Emergent CDMO Case Studies: Project Design & Implementation of Fill/Finish Technologies
      Aptar Pharma Launches HeroTracker Sense
      MasterControl Features Quality Management and Manufacturing Execution Systems
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Mielle Organics Welcomes Steve Pamon to Advisory Board
      Makeup Revolution Expands into Walgreens
      Nu Skin Joins EcoBeautyScore Consortium
      Happi

      Latest Breaking News From Happi

      Revolution Beauty Expands Makeup Revolution Into Walgreens
      Barentz Develops Electronic Personal Care Product Guide
      P&G Temporarily Closes Downtown Cincinnati Office Due to Potential Security Concerns
      Ink World

      Latest Breaking News From Ink World

      Nazdar Ink Technologies to Showcase Latest Ink Innovations at FESPA Global Print Expo 2022
      Epson Introduces First Direct-to-Fabric Printer for North America
      ProAmpac Facilities Secure Safety Awards 2022
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      In-Mold Decorating Association announces 2022 IMDA Awards Competition
      Essentra Packaging invests in Landa Nanographic press
      Nazdar to manufacture VFP electronic ink for US Market
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      'Right' Hygiene Conference to be Held in June
      Freudenberg to Present Battery Pack and Liquid Absorbers at Battery Show
      H&V Appoints Vice President and General Counsel
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Envista To Acquire Osteogenics
      Exactech Earns Breakthrough Status for JointMedica's Polymotion Hip Resurfacing
      Orthotic Brace Suppliers Convicted in $6.5M Fraud Scheme
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Emerson Earns Third Consecutive 2022 ENERGY STAR Partner of the Year Award
      First Solar to Sell Japan Project Development, O&M Platforms to PAG Real Assets
      Jabil Strengthens Additive Manufacturing Offerings

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login